Drug intelligence / Profile preview

MYR-001

Development stage: Preclinical
Lead developer: Omic
Modality: Small Molecules

Overview

MYR-001 is a small molecule therapeutic candidate currently in the lead optimization stage, developed by Omic Analytics. It is designed to target the myristoylation pathway, a post-translational modification process where the 14-carbon fatty acid myristate is attached to the N-terminal glycine of specific proteins. This pathway is critical for the membrane localization and functional activation of various proteins involved in signal transduction, cellular growth, and viral replication. MYR-001 is being investigated for its potential in treating both cancer and infectious diseases, leveraging the dependency of certain tumors and pathogens on myristoylation for survival and proliferation.

Other names: MYR-001MYR001MYR 001

Targets

NMT (Glycylpeptide N-tetradecanoyltransferase (N-myristoyltransferase))

Beyond the preview

Go deeper on MYR-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MYR-001.

Explore the full profile